ScoreWhy is Zhejiang Orient Gene Biotech Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of -4.97% and Operating profit at -204.30% over the last 5 years
- NET SALES(9M) At CNY 586.59 MM has Grown at 20%
- NET PROFIT(HY) Higher at CNY -376.26 MM
- RAW MATERIAL COST(Y) Fallen by -314.45% (YoY)
2
Risky -
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -24.10%, its profits have risen by 6.5%
3
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -24.10% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Zhejiang Orient Gene Biotech Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Zhejiang Orient Gene Biotech Co., Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Zhejiang Orient Gene Biotech Co., Ltd.
-22.08%
-0.26
37.05%
China Shanghai Composite
15.19%
1.01
14.58%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-4.97%
EBIT Growth (5y)
-204.30%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.40
Sales to Capital Employed (avg)
0.16
Tax Ratio
3.31%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
471.21%
ROE (avg)
28.64%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.79
EV to EBIT
-3.30
EV to EBITDA
-4.59
EV to Capital Employed
0.66
EV to Sales
3.34
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-19.97%
ROE (Latest)
-9.02%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend6What is working for the Company
NET SALES(9M)
At CNY 586.59 MM has Grown at 20%
NET PROFIT(HY)
Higher at CNY -376.26 MM
RAW MATERIAL COST(Y)
Fallen by -314.45% (YoY
-2What is not working for the Company
DEBT-EQUITY RATIO
(HY)
Highest at -39.4 %
Here's what is working for Zhejiang Orient Gene Biotech Co., Ltd.
Net Profit
Higher at CNY -376.26 MM
than preceding 12 month period ended Mar 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (CNY MM)
Net Sales
At CNY 586.59 MM has Grown at 20%
Year on Year (YoY)MOJO Watch
Near term sales trend is positive
Net Sales (CNY MM)
Raw Material Cost
Fallen by -314.45% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Zhejiang Orient Gene Biotech Co., Ltd.
Debt-Equity Ratio
Highest at -39.4 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed
Debt-Equity Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
